By performing an in depth histological and molecular characterization of the tumor states following NR2F2 genetic achieve and lack of features research throughout tumor development, the authors unravel the molecular mechanisms by which NR2F2 regulates malignant tumor development, and tumor progress. NR2F2 promotes tumor cell proliferation, and invasive options, whereas repressing cell loss of life, tumor differentiation and immune cell infiltration of the tumor.
“One of the most remarkable findings of this study is the demonstration that inactivation of NR2F2 promotes tumor differentiation, leading to tumor regression. Despite the spectacular efficacity of pro-differentiation therapy for the treatment of pro-myelomonocytic leukemia, very few pro-differentiation therapies are currently used to treat solid cancers. The development of NR2F2 inhibitors should keep in check many essential cancer functions and is thus a very promising strategy for the development of novel anticancer therapy,”, feedback Pr Cedric Blanpain, the senior creator of this research.
Cdric Blanpain, along with ULB, and personal and public buyers based an organization referred to as ChromaCure to find and develop first-in-class small molecule therapeutics concentrating on NR2F2 for unmet medical wants in oncology.